HealthDay News — Screening detection is associated with increased survival rates even for stage IV breast cancer, according to a study published online Feb. 19 in the Journal of the National Cancer ...

In the phase 3 VERIFY trial, rusfertide was associated with a significantly higher proportion of patients achieving clinical response compared with placebo.

The approval was based on a cohort of treatment-naïve patients in the Beamion LUNG-1 trial who had unresectable or metastatic, non-squamous NSCLC with HER2 tyrosine kinase domain mutations.

Investigators sought to determine the effect of “Smart PSA” guidelines on screening behavior and biopsy outcomes among Black men.

HealthDay News — A blood test designed to find cancer early did not work as hoped in a major new study, according to the company that makes it. The test, called Galleri, failed to lower the number of ...

Researchers explain Care Coordination and Collaboration Programs in Oncology, which use patient navigators to ease disparities in cancer care for Native American patients.

In the AMPLIFY study, fixed-duration venetoclax-acalabrutinib reduced the risk of disease progression or death by 35% compared with chemoimmuntherapy.

Chenxi Jiang, M.P.H., from the American Cancer Society in Atlanta, and colleagues used data from the U.S. Cancer Statistics Database to compare differences in cervical cancer incidence rates for women ...

Researchers assessed whether venetoclax-obinutuzumab would be safe and effective in fit and unfit patients with previously untreated CLL.

In this study, researchers aimed to fill gaps in the knowledge of treatment management and outcomes in melanoma patients aged 75 years and older.

Whether BCG strains other than BCG TICE are safe and effective for treating high-grade NMIBC warrants rigorous testing.

SHERBET, an individual patient data post hoc pooled analysis of 5 prospective trials, compared HDR-BT with SBRT in patients with intermediate-risk prostate cancer.